The health technology assessment agency has recommended in final draft guidance that the drug be used on the NHS in England, Wales and Northern Ireland to treat advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults who have had a complete or partial response to first-line platinum-based chemotherapy.
Eligible patients must also be without a BRCA mutation and have homologous recombination deficiency (HRD) positive or negative disease, as well as not be able to receive bevacizumab…
